Edition:
India

Bioblast Pharma Ltd (ORPN.OQ)

ORPN.OQ on NASDAQ Stock Exchange Capital Market

1.96USD
8:09pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.96
Open
$1.95
Day's High
$1.96
Day's Low
$1.95
Volume
700
Avg. Vol
11,231
52-wk High
$7.75
52-wk Low
$1.64

Latest Key Developments (Source: Significant Developments)

Bioblast Pharma reports Q3 loss per share $0.32
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Bioblast Pharma Ltd :Bioblast Pharma reports third quarter 2017 financial results.Q3 loss per share $0.32.  Full Article

Bioblast Pharma reports Q2 loss per share $0.22
Thursday, 25 Aug 2016 

Bioblast Pharma Ltd : Bioblast Pharma reports second quarter 2016 financial results .Q2 loss per share $0.22.  Full Article

Bio Blast Pharma updates corporate plans
Thursday, 9 Jun 2016 

Bio Blast Pharma Ltd : Says Fredric Price, executive chairman, will lead company's day-to-day operational efforts . Intends to enroll more than 70 patients in phase 2B clinical trial at up to 15 sites in United States and Canada . Plans to initiate a phase 2B trial with trehalose IV solution in OPMD during second half of 2016 . Colin Foster, Bioblast's president and CEO, will be leaving his operational position . Made decision to streamline company expenditures and downsize management team . Up to 8 employees have left or will be leaving co, including chief commercial officer, chief corporate development officer, CFO .Bio Blast Pharma updates corporate plans.  Full Article

Bioblast Pharma reports Q1 loss per share $0.32
Wednesday, 25 May 2016 

Bio Blast Pharma Ltd : Bioblast Pharma reports first quarter 2016 financial results .Q1 loss per share $0.32.  Full Article

Bio Blast Pharma Ltd announces pricing of $6.7 mln Registered Direct Offering
Thursday, 17 Mar 2016 

Bio Blast Pharma Ltd:Says has entered into definitive securities purchase agreements with two healthcare focused institutional investors providing for the issuance of about 2.16 million ordinary shares at a purchase price per share of $3.10.Roth Capital Partners and Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the exclusive placement agents for this transaction.  Full Article

BRIEF-Bioblast Pharma reports Q3 loss per share $0.32

* Bioblast Pharma reports third quarter 2017 financial results